ASTX727 and Retifanlimab-dlwr Trial for Advanced Merkel Cell Cancer Initiated
A clinical trial is underway to evaluate the safety and efficacy of ASTX727 combined with retifanlimab in patients with advanced Merkel cell carcinoma after progression on anti-PD-(L)1 therapy.